Alan B. Lancz & Associates, Inc. Eli Lilly & CO Transaction History
Alan B. Lancz & Associates, Inc.
- $94.4 Million
- Q4 2023
A detailed history of Alan B. Lancz & Associates, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 1,775 shares of LLY stock, worth $1.62 Million. This represents 1.1% of its overall portfolio holdings.
Number of Shares
1,775
Previous 2,125
16.47%
Holding current value
$1.62 Million
Previous $1.14 Million
9.38%
% of portfolio
1.1%
Previous 1.3%
Shares
4 transactions
Others Institutions Holding LLY
# of Institutions
3,725Shares Held
738MCall Options Held
7.09MPut Options Held
7.24M-
Lilly Endowment Inc Indianapolis, IN98.9MShares$90.4 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA72.7MShares$66.5 Billion1.14% of portfolio
-
Black Rock Inc. New York, NY65.3MShares$59.7 Billion1.2% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.4MShares$47 Billion27.92% of portfolio
-
State Street Corp Boston, MA34.3MShares$31.3 Billion1.21% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $869B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...